Australia markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.38-0.12 (-1.85%)
At close: 04:00PM EDT
6.38 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 113.37M
Enterprise value 94.24M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.29
Enterprise value/revenue N/A
Enterprise value/EBITDA -4.12

Trading information

Stock price history

Beta (5Y monthly) 0.27
52-week change 3-55.73%
S&P500 52-week change 324.19%
52-week high 318.65
52-week low 36.20
50-day moving average 38.34
200-day moving average 310.10

Share statistics

Avg vol (3-month) 393.14k
Avg vol (10-day) 350.91k
Shares outstanding 517.77M
Implied shares outstanding 618.1M
Float 85.11M
% held by insiders 157.21%
% held by institutions 117.09%
Shares short (15 Apr 2024) 4822.55k
Short ratio (15 Apr 2024) 49.59
Short % of float (15 Apr 2024) 48.93%
Short % of shares outstanding (15 Apr 2024) 44.63%
Shares short (prior month 15 Mar 2024) 4766.09k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-69.14%
Return on equity (ttm)-168.51%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-22.26M
Diluted EPS (ttm)-1.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)19.13M
Total cash per share (mrq)1.08
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)2.75
Book value per share (mrq)0.70

Cash flow statement

Operating cash flow (ttm)-15.95M
Levered free cash flow (ttm)-7.83M